Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications

Abstract excerpt

Around 80-90% of prostate cancer (PCa) cases are dependent on androgens at initial diagnosis; hence, androgen ablation therapy directed toward a reduction in serum androgens and the inhibition of androgen receptor (AR) is generally the first therapy adopted. However, the patient's response to androgen ablation therapy is variable, and 20-30% of PCa cases become castration resistant (CRPCa). Several mechanisms can...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer, Lipids, and Metabolism
• Share to Cancer-related gene regulation
• Share to Prostate Cancer Treatment and Research